

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14307 A1

(51) International Patent Classification⁷: **C07D 403/10**,
A61K 31/41, A61P 7/02

(21) International Application Number: PCT/US01/25324

(22) International Filing Date: 11 August 2001 (11.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,713 11 August 2000 (11.08.2000) US

(71) Applicant (*for all designated States except US*): **AXYS
PHARMACEUTICALS, INC.** [US/US]; 180 Kimball
Way, South San Francisco, CA 94080 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LEAHY, Ellen, M.**
[US/US]; 1185 Camellia Court, San Leandro, CA 94577
(US).

(74) Agents: **MONTGOMERY, Wayne, W.** et al.; Axys Phar-
maceuticals, Inc., 180 Kimball Way, South San Francisco,
CA 94080 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: FACTOR VIIA INHIBITORS

(57) Abstract: The present invention provides novel compounds of Formula (I): its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of Factor VIIa (fVIIa), and have utility as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.



WO 02/14307 A1

FACTOR VIIA INHIBITORS

This application is based on and claims priority from U.S. Provisional
5 Application S.N. 60/224,713 filed on August 11, 2000.

FIELD OF INVENTION

The present invention relates to compounds of Formula I which are useful as
factor VIIA (fVIIa) inhibitors.

10

BACKGROUND OF THE INVENTION


Factor VIIa (herein after "fVIIa"), the converting enzyme of factor X to factor
Xa, has emerged as an alternative target to thrombin or factor Xa for the treatment of
thromboembolic disorders. A variety of compounds have been developed as
15 potential FVIIa inhibitors.

Kunitada and Nagahara in Current Pharmaceutical Design, 1996, Vol. 2,
No.5, report amidinobenzyl compounds as fVIIa and thrombin inhibitors. Disclosed
in U.S. Patent No. 5,576,343 are aromatic amidine derivatives and salts thereof, as
reversible inhibitors of fVIIa. These compounds comprise amidino substituted
20 indolyl, benzofuranyl, benzothieryl, benzimidazolyl, benzoxazolyl, benzothiazolyl,
naphthyl, tetrahydronaphthyl and indanyl groups, attached to a substituted phenyl
ring by an alkylene group having from 1 to 4 carbon atoms.

In spite of the above discussed efforts, a desirable treatment for
thromboembolic disorders based on fVIIa inhibition remains elusive. One of the
25 hurdles that must be overcome to generate an effective therapeutic is the creation of
fVIIa inhibitors with desirable pharmaceutical attributes. These attributes, (e.g.
clearance, mean residence time in plasma, terminal phase half-life, bioavailability,
and solubility) significantly affect the ultimate utility of a fVIIa inhibitors. Potent
inhibitors, without drug-like properties are unsuitable as thromboembolic therapies.
30 There is thus a need for novel compounds that will be not only effective in inhibiting
blood-clotting enzymes such as fVIIa but will also perform as pharmaceutical agents.
We have surprisingly found that compounds of the present invention have desirable
clearance, mean residence time and increased terminal phase half-life.

SUMMARY OF THE INVENTION

5 The present invention provides compounds of Formula I:



Formula I

10 its prodrug forms or pharmaceutically acceptable salts of , wherein

R^1 represents OH;

R^2 represents phenyl or nitrophenyl;

R^3 represents H;

R^4 represents $(CH_2)_{0-2}$ -tetrazolyl or $(CH_2)_{0-2}$ -triazolyl;

15 R^5 represents H;

R^6 represents H or CH_2 -phenyl;

R^7 represents amino, amidino or guanidino;

R^8 represents H; and

R^9 represents H.

20

DETAILED DESCRIPTION

The present invention in its preferred embodiment provides a compound of Formula I selected from:

2-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

25 2-[2-Hydroxy-3'-nitro-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;


2-[2-Hydroxy-3'-nitro-5-(1*H*-tetrazol-5-ylmethyl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

2-[2-Hydroxy-5-(1*H*-tetrazol-5-ylmethyl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

2-[2-Hydroxy-5-(3*H*-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamide; and
2-(2-Hydroxy-5-tetrazol-1-yl-biphenyl-3-yl)-1*H*-indole-5-carboxamide.

Another preferred embodiment provides a compound of Formula I

5



Formula I

10 its prodrug forms or pharmaceutically acceptable salts of, wherein

R^1 represents OH;

R^2 represents phenyl;

R^3 represents H;

R^4 represents tetrazolyl;

15 R^5 represents H;

R^6 represents H or CH_2 -phenyl;

R^7 represents amino, amidino or guanidino;

R^8 represents H; and

R^9 represents H.

20 Provided in yet another preferred embodiment is a compound of Formula I:
wherein

R^1 represents OH;

R^2 represents nitrophenyl;

R^3 represents H;

25 R^4 represents tetrazolyl;

R^5 represents H;

R^6 represents H;

R⁷ represents amidino;

R⁸ represents H; and

R⁹ represents H.

Yet another preferred embodiment provides a compound of Formula I:

5 wherein

R¹ represents OH;

R² represents nitrophenyl;

R³ represents H;

R⁴ represents triazolyl;

10 R⁵ represents H;

R⁶ represents H;

R⁷ represents amidino;

R⁸ represents H; and

R⁹ represents H.

15 Another aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according of Formula I, or a pharmaceutically acceptable salt thereof.

20 Yet another aspect of the present invention provides a method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.

SYNTHESIS

25 The novel compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. Described herein are some of the preferred synthetic methods for synthesizing novel compounds of the present invention. All temperatures reported herein are in degrees Celsius (°C), unless indicated otherwise.


30 The novel compounds of Formula I can be prepared using the reactions and synthetic techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of


organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.

It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for the protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups in Organic Synthesis, Wiley and Sons, 1991). Proton NMR's (^1H NMR) were obtained using deuterated solvents such as dimethyl sulfoxide (DMSO-d_6), deuterated chloroform (CDCl_3), or other appropriate solvents.

EXPERIMENTAL

Scheme I





Preparation of 2-[2-hydroxy-3-nitro-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine, **Ex. 1**

5

Step-A: 1-[2-Hydroxy-3-nitro-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-ethanone **2**:

A solution of 1-[3-bromo-2-hydroxy-5-(1*H*-tetrazol-5-yl)-phenyl]-ethanone (**1**, 1.07g, 3.78 mmoles) and 3-nitrophenylboronic acid (0.69g, 5.67 mmoles) in ethanol (8mL) was mixed with toluene (25mL), 2M Na₂CO₃ (2.8mL) and the resulting mixture
 10 flushed with nitrogen. The nitrogen flushed reaction mixture then was combined with Pd(PPh₃)₄ (0.44g, 0.38mmoles) and the resulting solution was refluxed from about 8 to about 16 hours. The reaction mixture then was cooled to ambient temperature, acidified with 1N HCl and extracted with EtOAc (2x150mL). The combined organic
 15 extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated to afford compound **2** product as a colorless oil (1.22, 100%).
 MS (ESI, M⁺+1): Calc. 325.08; Found 325.9.

Steps-B,C: 2-[2-Hydroxy-3-nitro-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine **Ex. 1**:


20 A solution of 1-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-ethanone (**2**, 1.20g, 3.69 moles), 4-hydrazinobenzamidine (1.74g, 7.80 mmoles) and DIEA (2.72 mL, 15.6 mmoles) in EtOH (50 mL) was refluxed from about 8 to about 16 hours. As the reaction proceeded, the yellow colored hydrazone precipitated out of solution. The reaction mixture was cooled and concentrated under reduced pressure to yield a
 25 yellowish powder. The yellowish powder was washed with acetonitrile and dried to yield about 1.50 g. The dry hydrazone was mixed with polyphosphoric acid (5 mL) and the resulting mixture was agitated at a temperature of about 165°C for about an

hour. The agitated mixture then was cooled and mixed with ice to form a brownish precipitate which was purified by reverse phase HPLC and lyophilized to afford the product as a cream colored solid (50mgs, 3%).


MS (ESI, $M^+ + 1$): Calc. 440.13; Found 440.6.

5

Scheme II



10



Preparation of 2-[2-hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamide Ex. 2

Step-(i): 3-Acetyl-4-hydroxy-benzonitrile **12**

A solution of 5-bromo-2-hydroxyacetophenone (**11**, 10.00g, 46.5 mmoles) in anhydrous DMF (25mL) was mixed with copper cyanide (6.25g, 69.75 mmoles) and the resulting reaction mixture was heated for about 8 to 16 hours at a temperature of about 160°C. The reaction mixture was cooled to room temperature and mixed with ether, the ether mixture was filtered through celite and the filtrate concentrated to afford a solid which was purified by flash column chromatography through silica using Hexane/EtOAc (4:1) as eluant to yield compound **12** as a clear colorless oil (5.25g, 70%).

¹H-NMR (DMSO- δ_6) d: 8.31 (s, 1H), 7.92 (d, 1H, J= 8.4 Hz), 7.12 (d, 1H, J= 8.7 Hz), 2.65 (s, 3H).

Step-(ii): 1-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-phenyl]-ethanone **13**

A solution of 3-acetyl-4-hydroxybenzonitrile **12** (2.23g, 13.97 mmoles) in toluene was mixed with azidotributyltin (5.74mL, 20.96 mmoles) and the resulting mixture was refluxed for about 8 to 18 hours. The reaction mixture was cooled to ambient temperature under a stream of nitrogen and then was mixed with 6N HCl (10mL). The resulting mixture was agitated at room temperature for about 30 minutes, and then was concentrated under reduced pressure to yield a tan colored

solid. Trituration of the solid with hexane afforded compound 13 as a pale tan colored solid (2.80g, 99%).

MS (ESI, $M^+ + 1$): Calc. 204.06; Found 205.0.

5 Step-(iii): 1-[3-Bromo-2-hydroxy-5-(1*H*-tetrazol-5-yl)-phenyl]-ethanone 14

A solution of 1-[2-hydroxy-5-(1*H*-tetrazol-5-yl)-phenyl]-ethanone (13, 1.00g, 4.9 mmoles) in anhydrous DMF (10mL) was mixed with N-bromosuccinimide (1.31g, 7.45 mmoles) and the resulting reaction mixture was agitated at 65°C for two hours. The reaction mixture then was diluted with EtOAc, washed with water and extracted with EtOAc (2x100mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated to afford the title compound of formula 14 as a pale yellow oil (1.24g, 89%).

MS (ESI, $M^+ + 1$): Calc. 281.98; Found 283.0.

15

Step-(iv): 1-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-ethanone 15

A solution of 1-[3-bromo-2-hydroxy-5-(1*H*-tetrazol-5-yl)-phenyl]-ethanone (14, 1.24g, 4.38 mmoles) and benzene boronic acid (0.80g, 6.57 mmoles) in ethanol (8mL) was mixed with toluene (25mL), 2M Na_2CO_3 (3.3mL) and the resulting mixture flushed with nitrogen. $\text{Pd}(\text{PPh}_3)_4$ (0.51g, 0.44mmoles) was added and the resulting reaction mixture was refluxed for up to 18 hours. The reaction mixture then was acidified with 1N HCl and extracted with EtOAc (2x150mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated to afford the title compound of formula 15 as a colorless oil (1.15, 93%).

25

MS (ESI, $M^+ + 1$): Calc. 280.102; Found 281.0.

Steps-(v),(vi): 2-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine **Ex. 2**:

30 A solution of 1-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-ethanone 15 (0.500g, 1.77 moles), 4-hydrazinobenzamidine (0.79g, 3.53 mmoles) and DIEA (1.23 mL, 7.06 mmoles) in EtOH (25 mL) was refluxed for up to 18hours. As the reaction proceeded, a yellow colored hydrazone precipitated out of the solution. The reaction

mixture was cooled and the solvents removed under reduced pressure to yield a yellow powder. The yellow powder was washed with acetonitrile and isolated by vacuum filtration (0.45g, %). The yellow powder (hydrazone) was mixed with polyphosphoric acid (1 mL) and the resulting mixture was agitated at a temperature of about 165°C for about an hour. The agitated mixture then was cooled and mixed with ice to form a brownish precipitate which was purified by reverse phase HPLC and lyophilized to afford the title compound, **Ex. 2**, as a cream colored solid (25 mgs, 2%).

MS (ESI, $M^+ + 1$): Calc. 395.15; Found 395.6.

UTILITY

The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example unstable angina, first or recurrent ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to the inhibition of Factor VIIa (fVIIa) and Factor Xa (fXa).

The fVIIa K_i apparent determinations were made in 50 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 5 mM $CaCl_2$, 0.05% Tween-20, 25 nM tissue factor, 1.5 mM EDTA and 10 % dimethylsulfoxide. Human factor VIIa (7 nM) was allowed to react with the substrate (500 μ M of CH_3SO_2 -D-CHA-But-Arg-pNA) in the presence of eight different inhibitor concentrations. Hydrolysis of the chromogenic substrate was followed spectrophotometrically at 405 nm for five minutes. This enzyme assay yields linear progression curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (Batch K_i ; Peter Kuzmic, BioKin, Ltd., Madison, WI) were used to determine the K_i app.

The fXa K_i apparent determinations were made in 50 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 5 mM $CaCl_2$, 0.05% Tween-20, and 1.5 mM EDTA.

Human Factor XA (2.8 nM) was allowed to react with the substrate (1 mM CH₃OCO-D-CHA-Gly-Arg-pNA) in the presence of eight different inhibitor concentrations. Hydrolysis of the chromogenic substrate was followed spectrophotometrically at 405 nm for five minutes. This enzyme assay yields
5 linear progression curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (Batch Ki; Peter Kuzmic, BioKin, Ltd., Madison, WI) were used to determine the Ki app.

DEFINITIONS

10 As used herein, the following terms and abbreviations have the following meaning, unless indicated otherwise.


The term "prodrug" is intended to represent covalently bonded carriers which are capable of releasing the active ingredient of Formula I, when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs *in*
15 *vivo*. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or *in vivo*. Prodrugs of compounds of Formula I include compounds wherein a hydroxy, amidino, guanidino, amino,
20 carboxylic or a similar group is modified.

"Pharmaceutically acceptable salts" is as understood by one skilled in the art. Thus a pharmaceutically acceptable salt includes acid or base salts of compounds of Formula I. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts,
25 organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton,
30 PA, 1985, which is incorporated herein by reference.

CLAIMS

1. A compound of Formula I

5



Formula I

- 10 its prodrug forms or pharmaceutically acceptable salts of,
wherein

R¹ represents OH;

R² represents phenyl or nitrophenyl;

R³ represents H;

- 15 R⁴ represents (CH₂)₀₋₂-tetrazolyl or (CH₂)₀₋₂-triazolyl;

R⁵ represents H;

R⁶ represents H or CH₂-phenyl;

R⁷ represents amino, amidino or guanidino;

R⁸ represents H; and

- 20 R⁹ represents H.

2. A compound of Claim 1 selected from

2-[2-Hydroxy-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;


2-[2-Hydroxy-3'-nitro-5-(1*H*-tetrazol-5-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

- 25 2-[2-Hydroxy-3'-nitro-5-(1*H*-tetrazol-5-ylmethyl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

2-[2-Hydroxy-5-(1*H*-tetrazol-5-ylmethyl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine;

2-[2-Hydroxy-5-(3*H*-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1*H*-indole-5-carboxamidine; and
 2-(2-Hydroxy-5-tetrazol-1-yl-biphenyl-3-yl)-1*H*-indole-5-carboxamidine.

3. A compound of Formula I



Formula I

its prodrug forms or pharmaceutically acceptable salts of,

wherein

R^1 represents OH;

R^2 represents phenyl;

R^3 represents H;

R^4 represents tetrazolyl;

R^5 represents H;


R^6 represents H;

R^7 represents amidino;

R^8 represents H; and

R^9 represents H.

4. A compound of Formula I



Formula I


wherein

- 10 R¹ represents OH;
R² represents nitrophenyl;
R³ represents H;
R⁴ represents tetrazolyl;
R⁵ represents H;
15 R⁶ represents H;
R⁷ represents amidino;
R⁸ represents H; and
R⁹ represents H.

20

25

5. A compound of Formula I



5

Formula I

its prodrug forms or pharmaceutically acceptable salts of,
wherein

R¹ represents OH;

10 R² represents phenyl;

R³ represents H;

R⁴ represents triazolyl;

R⁵ represents H;

R⁶ represents H;

15 R⁷ represents amidino;


R⁸ represents H; and

R⁹ represents H.

20

25

6. A compound of Formula I



5

Formula I

its prodrug forms or pharmaceutically acceptable salts of,
wherein

R¹ represents OH;

10 R² represents nitrophenyl;

R³ represents H;

R⁴ represents triazolyl;

R⁵ represents H;

R⁶ represents H;

15 R⁷ represents amidino;

R⁸ represents H; and

R⁹ represents H.

7. A pharmaceutical composition comprising a pharmaceutically acceptable
20 carrier and a therapeutically effective amount of a compound of Claim I, or a
pharmaceutically acceptable salt thereof.

8. A method for treating or preventing a thromboembolic disorder, comprising
administering to a patient in need thereof a therapeutically effective amount of a
25 compound of Claim 1 or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3, or a pharmaceutically acceptable salt thereof.
- 5 10. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt thereof.
- 10 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4, or a pharmaceutically acceptable salt thereof.
- 15 12. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt thereof.
- 20 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5, or a pharmaceutically acceptable salt thereof.
- 25 14. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Initial Application No

PCT, JS 01/25324

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D403/10 A61K31/41 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 576 343 A (NAGAHARA TAKAYASU ET AL) 19 November 1996 (1996-11-19) cited in the application abstract; claims 1,2,9,10 ----	1-14
A	WO 97 21707 A (MERCK & CO INC; GOULET MARK (US); ASHTON WALLACE T (US); CHU LIN () 19 June 1997 (1997-06-19) claims 1-10 ----	1,7
A	US 5 849 764 A (WYVRATT MATTHEW J ET AL) 15 December 1998 (1998-12-15) claims 1,10,11,16 ----	1,7
A	US 4 118 561 A (LEDIG KURT W) 3 October 1978 (1978-10-03) column 5, line 53 - line 60 -----	1

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

11 December 2001

Date of mailing of the international search report

18/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/25324

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5576343	A	19-11-1996	AT 136293 T	15-04-1996
			AU 666137 B2	01-02-1996
			AU 2747092 A	06-05-1993
			BG 63237 B2	29-06-2001
			CA 2081836 A1	01-05-1993
			CN 1072677 A ,B	02-06-1993
			CN 1168885 A	31-12-1997
			CN 1168886 A ,B	31-12-1997
			CZ 284381 B6	11-11-1998
			DE 69209615 D1	09-05-1996
			DE 69209615 T2	09-01-1997
			DK 540051 T3	06-05-1996
			EE 3024 B1	17-06-1996
			EP 0540051 A1	05-05-1993
			ES 2088073 T3	01-08-1996
			FI 924932 A	01-05-1993
			GR 3019832 T3	31-08-1996
			HK 1002999 A1	30-09-1998
			HR 921147 B1	30-04-1999
			HR 921147 A1	31-10-1995
			HU 65890 A2	28-07-1994
			IL 103564 A	06-12-1998
			JP 10291931 A	04-11-1998
			JP 2879718 B2	05-04-1999
			JP 5208946 A	20-08-1993
			KR 205152 B1	01-07-1999
			MX 9206295 A1	01-08-1993
			NO 302948 B1	11-05-1998
			NZ 244936 A	26-05-1995
			PL 170312 B1	29-11-1996
			RU 2139851 C1	20-10-1999
			SG 78251 A1	20-02-2001
			SK 327692 A3	13-04-1999
			US 5962695 A	05-10-1999
			US 5620991 A	15-04-1997
			US 5866577 A	02-02-1999
			ZA 9208276 A	06-05-1993
WO 9721707	A	19-06-1997	AU 707277 B2	08-07-1999
			AU 1287697 A	03-07-1997
			CA 2240111 A1	19-06-1997
			CN 1209129 A	24-02-1999
			CZ 9801831 A3	14-10-1998
			EE 9800180 A	15-12-1998
			EP 0882040 A1	09-12-1998
			HU 9903686 A2	28-09-2000
			JP 11502538 T	02-03-1999
			JP 3092946 B2	25-09-2000
			JP 2000212161 A	02-08-2000
			NO 982730 A	13-08-1998
			PL 327397 A1	07-12-1998
			SK 77498 A3	11-01-1999
			US 6197975 B1	06-03-2001
			WO 9721707 A1	19-06-1997
US 5849764	A	15-12-1998	AU 709090 B2	19-08-1999
			AU 1281997 A	03-07-1997
			CA 2240048 A1	19-06-1997

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/25324

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5849764	A	CN 1208413 A	17-02-1999
		CZ 9801832 A3	16-09-1998
		EE 9800181 A	15-12-1998
		EP 0871624 A1	21-10-1998
		HU 9902121 A2	28-10-1999
		JP 11501329 T	02-02-1999
		JP 2000186039 A	04-07-2000
		NO 982731 A	13-08-1998
		PL 327132 A1	23-11-1998
		SK 77598 A3	11-01-1999
		WO 9721703 A1	19-06-1997
US 4118561	A	03-10-1978	AU 507828 B2
			28-02-1980
			AU 2668777 A
			04-01-1979
			BE 856647 A1
			09-01-1978
			CA 1093555 A1
			13-01-1981
			CH 635842 A5
			29-04-1983
			CH 636616 A5
			15-06-1983
			CH 634069 A5
			14-01-1983
			DE 2731039 A1
			19-01-1978
			DK 309977 A
			10-01-1978
			FR 2357563 A1
			03-02-1978
			GB 1579678 A
			19-11-1980
			IE 45427 B1
			25-08-1982
			IN 147488 A1
			15-03-1980
			JP 53009796 A
			28-01-1978
			JP 62054111 B
			13-11-1987
			MX 5133 E
			28-03-1983
			NL 7707658 A
			11-01-1978
			PH 13539 A
			26-06-1980